Apimeds(APUS)
MATAWAN, NJBiotechnology
Focus: Apimeds is a public biotech company focused on developing honey bee venom-derived therapeutics for neurological and musculoskeletal diseases. The company is in early clinical stages with minimal commercial revenue and operates at a pre-revenue scale.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Apimeds
AI assessmentNot HiringNo open roles listed right now. Follow Apimeds to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
honeybee venom
Osteoarthritis of the KneeClinical Trials (1)
NCT00949754Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation
Phase 2Help build intelligence for Apimeds
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.